← All trials
NCT01690338
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2012
- Primary completion
- Oct 1, 2014
- Completion date
- Dec 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 6090
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Peking UniversityLead sponsor
- Peking UniversityOverall official - principal investigator
- Peking UniversityReponsible party - principal investigator
- Eastern Hepatobiliary Surgery HospitalCollaborator
- Central South UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Fudan UniversityCollaborator
- Sichuan UniversityCollaborator
- Southern Medical UniversityCollaborator
- Tsinghua UniversityCollaborator
- Zhejiang UniversityCollaborator
- Guangzhou Medical UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Xinjiang Medical UniversityCollaborator
- Zhengzhou UniversityCollaborator
- China Medical UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Jiao Tong UniversityCollaborator
- Hebei UniversityCollaborator
- Huazhong University of Science and TechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.